Drug Trial Radar · NCT02725268
A Study of Sapanisertib, Combination of Sapanisertib With MLN1117, Paclitaxel and Combination of Sapanisertib With Paclitaxel in Women With Endometrial Cancer
Last checked: Nov 19, 2026Latest source record: Nov 24, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
241
Actual
Start
Apr 1, 2016
Primary completion
Jul 2, 2019
Study completion Oct 30, 2020
Sponsor
- Lead sponsor
- Millennium Pharmaceuticals, Inc.Takeda (TAK)
- Sponsor type
- Industry
- Collaborators
- European Network of Translational Research in Ovarian Cancer - EUTROC; European Network of Individualized Treatment in Endometrial Cancer - ENITEC
- First posted
- Mar 31, 2016
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary purpose of this study is to determine if sapanisertib in combination with weekly paclitaxel improves progression-free survival (PFS) compared to weekly paclitaxel alone.
Conditions
- Endometrial Neoplasms
Interventions
PaclitaxelDrug
Paclitaxel intravenous solution.
SapanisertibDrug
Sapanisertib capsules.
MLN1117Drug
MLN1117 capsules.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression Free Survival (PFS)Time frame: Up to approximately 30 months
Locations
78 sites in 10 countries. Site status is shown where the registry gives one.
University of Alabama Comprehensive Cancer Center
Birmingham, Alabama
University of Arizona Cancer Center
Phoenix, Arizona
Marin Cancer Care
Greenbrae, California
University of California San Diego Medical Center
La Jolla, California
University of California at San Francisco (PARENT)
San Francisco, California
Stanford School of Medicine
Stanford, California
H. Lee Moffitt Cancer Center and Research Institute, Inc
Tampa, Florida
Florida Cancer Specialists
West Palm Beach, Florida
Augusta University
Augusta, Georgia
Franciscan St. Francis Health
Indianapolis, Indiana
University of Kansas Medical Center Research Institute, Inc.
Westwood, Kansas
Massachusetts General Hospital Cancer Center
Boston, Massachusetts
Washington University
St Louis, Missouri
NYU Langone Medical Center Clinic
New York, New York
Memorial Sloan Kettering Cancer Center
New York, New York
Levine Cancer Institute
Charlotte, North Carolina
Oklahoma University Health Sciences Center
Oklahoma City, Oklahoma
Fox Chase Cancer Center
Philadelphia, Pennsylvania
University of Pittsburgh Medical Center Cancer Center at Magee-Womens Hospital
Pittsburgh, Pennsylvania
Sarah Cannon Research Institute
Nashville, Tennessee
University of Texas Southwestern Medical Center
Dallas, Texas
St George Hospital
Kogarah, New South Wales, Australia
Westmead Hospital
Westmead, New South Wales, Australia
Royal Brisbane and Women's Hospital
Herston, Queensland, Australia
Monash Medical Centre Clayton
Clayton, Victoria, Australia
Sunshine Hospital
Footscray, Victoria, Australia
Cabrini Hospital Malvern
Malvern, Victoria, Australia
Peter MacCallum Cancer Centre-East Melbourne
Melbourne, Victoria, Australia
Cliniques Universitaires Saint-Luc
Brussels, Belgium
UZ Leuven
Leuven, Belgium
Centre Hospitalier Universitaire de Liege Site Sart Tilman
Liège, Belgium
GasthuisZusters Antwerpen Sint-Augustinus
Wilrijk, Belgium
UZ Antwerpen
Edegem, Antwerpen, Belgium
Tom Baker Cancer Centre
Calgary, Alberta, Canada
Juravinski Cancer Clinic
Hamilton, Ontario, Canada
LHSC - Victoria Hospital
London, Ontario, Canada
Ottawa Hospital Cancer Centre
Ottawa, Ontario, Canada
University Health Network - Princess Margaret Cancer Centre
Toronto, Ontario, Canada
CHUM Hopital Notre-Dame
Montreal, Quebec, Canada
Charite - Universitaetsmedizin Berlin - Campus Virchow-Klinikum
Berlin, Germany
Showing 40 of 78 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.